CAL02 + Placebo
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumonia, Bacterial
Conditions
Pneumonia, Bacterial
Trial Timeline
Jul 22, 2023 → Sep 7, 2026
NCT ID
NCT05776004About CAL02 + Placebo
CAL02 + Placebo is a phase 2 stage product being developed by Eagle Pharmaceuticals for Pneumonia, Bacterial. The current trial status is active. This product is registered under clinical trial identifier NCT05776004. Target conditions include Pneumonia, Bacterial.
What happened to similar drugs?
20 of 20 similar drugs in Pneumonia, Bacterial were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05776004 | Phase 2 | Active |
Competing Products
20 competing products in Pneumonia, Bacterial